文献速递流行病学与生物统计真实世界研究与卫生经济

依从性对结直肠癌筛查成本效果的影响:一项建模研究

The impact of adherence on colorectal cancer screening cost-effectiveness: A modeling study.
PubMed 文献 · PLoS Med · 2025-11-26

研究开发多状态马尔可夫模型(CRC-SIM),模拟10万名40岁人群至79岁或死亡,评估多阶段筛查参与率对结直肠癌筛查策略健康获益与成本效果的影响。结果显示,与不筛查相比所有策略均减少结直肠癌病例和死亡并增加质量调整生命年,基于生物标志物的策略在相同参与率下优于传统方法;问卷联合粪便免疫化学试验最具成本效果(ICER=每获得1个QALY需2413美元),而基于生物标志物的非侵入性检测在当前假设下与问卷联合FIT策略相比不具备成本效果。

要点

  • 与不筛查相比,所有结直肠癌筛查策略均减少病例和死亡并增加QALYs。
  • 问卷联合FIT是最具成本效果的策略(ICER=每QALY 2413美元)。
  • 基于生物标志物的非侵入性检测在当前检测成本与相同参与率假设下与问卷联合FIT策略相比不具备成本效果。

核心结论

  • 提高筛查参与率可增强结直肠癌筛查的健康获益与成本效率。
  • 基于问卷的风险评估联合FIT在中国是一种具成本效果的策略,而基于生物标志物的非侵入性方法需要降低成本并提高参与率才能证明其应用合理性。

研究设计与样本

  • 开发多状态马尔可夫模型(CRC-SIM)评估多步骤参与对结直肠癌筛查的影响。
  • 模拟10万名40岁个体的假设队列,随访至79岁或死亡。
  • 建模两步筛查策略:初筛后结果阳性者行结肠镜检查。
  • 传统初筛方法包括:基于问卷的风险评估、粪便免疫化学试验(FIT)、问卷联合FIT;基于生物标志物的非侵入性初筛策略包括:符合中国国家药品监督管理局最低标准的假设检测(NMPAmin)、多靶点粪便DNA(mt-sDNA)检测和基于血液的策略。
  • 所有策略均建模为一次性筛查,计算增量成本效果比(ICER),并制作成本效果热图评估多步骤参与(以10%为步长建模)对经济结局的影响。

主要发现

  • 与不筛查相比,所有策略均减少结直肠癌病例、死亡并增加QALYs,基于生物标志物的策略在相同参与率下优于传统方法。
  • 在100%参与率下,问卷联合FIT预防224例(95%CI [157, 292])结直肠癌病例和151例(95%CI [109, 195])死亡,而NMPAmin预防312例(95%CI [257, 360])病例和210例(95%CI [175, 241])死亡。
  • 成本效果热图显示,初筛和随访结肠镜检查参与率每增加10%,ICER以非线性模式改善。
  • 问卷联合FIT是最具成本效果的策略(ICER=每获得1个QALY需2413美元)。
  • 在当前检测成本假设和相同参与率下,基于生物标志物的非侵入性检测与问卷联合FIT策略相比不具备成本效果。

关键数值与推荐

  • 在100%参与率下,问卷联合FIT预防224例(95%CI [157, 292])结直肠癌病例和151例(95%CI [109, 195])死亡。
  • 在100%参与率下,NMPAmin预防312例(95%CI [257, 360])结直肠癌病例和210例(95%CI [175, 241])死亡。
  • 问卷联合FIT的ICER=每获得1个QALY需2413美元。
  • 阈值分析:NMPAmin检测成本降至131.7美元以下或结肠镜参与率增至至少70%时,基于生物标志物的非侵入性筛查将具有成本效果。
  • 阈值分析:血液检测和mt-sDNA的结肠镜参与率增至至少50%时,基于生物标志物的非侵入性筛查将具有成本效果。

临床怎么用

  • 基于问卷的风险评估联合FIT在中国是一种具成本效果的结直肠癌筛查策略。
  • 基于生物标志物的非侵入性方法需要降低成本并提高参与率才能证明其应用合理性。
  • 研究结果为政策制定者优化结直肠癌筛查项目提供证据。

局限性

  • 局限性包括假设为一次性筛查场景;模型的未来版本和重复筛查证据的合并将解决这些局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adherence to colorectal cancer (CRC) screening remains suboptimal in many countries, reducing its cost-effectiveness. This study aimed to evaluate how multistage uptake rates influence the health benefit and cost-effectiveness of various CRC screening strategies in the Chinese population, incorporating both traditional and emerging screening methods. METHODS AND FINDINGS: We developed a multistate Markov model (CRC-SIM) to evaluate the impact of multistep uptake on CRC screening. A hypothetical cohort of 100,000 individuals aged 40 was simulated and followed until 79 or death. Two-step screening strategies were modeled: initial screening followed by colonoscopy after a positive result. Traditional initial screening methods include: questionnaire-based risk assessment, fecal immunochemical test (FIT), and questionnaire combined with FIT; Non-invasive biomarker-based initial strategies include a hypothetical test meeting the minimum standards of China National Medical Products Administration (NMPAmin), multitarget stool DNA (mt-sDNA) test, and blood-based strategies. All strategies were modeled as one-time screenings, with outcomes projected for CRC cases, deaths, quality-adjusted life years (QALYs), and lifetime costs. Incremental cost-effectiveness ratios (ICERs) were calculated, and a cost-effectiveness heatmap was conducted to assess the impact of multistep uptake (modeled in 10% steps) on economic outcomes. All strategies reduced CRC cases, deaths and increased QALYs compared to no screening, with biomarker-based strategies outperforming the traditional methods at the same uptake level (e.g., questionnaire combined with FIT prevented 224 (95% confidence interval (CI) [157, 292]) CRC cases and 151 (95% CI [109, 195]) deaths, whereas NMPAmin prevented 312 (95% CI [257, 360]) cases and 210 (95% CI [175, 241]) deaths at 100% uptake). The cost-effectiveness heatmap indicated that each 10% increase in initial and follow-up colonoscopy uptake improved ICERs in a non-linear pattern. The questionnaire combined with FIT was the most cost-effective strategy (ICER = $2,413 per QALY gained). Non-invasive biomarker-based tests were not cost-effective compared with the combined questionnaire and FIT strategy under current assumptions of test costs and identical uptake rate. Threshold analysis showed that non-invasive biomarker-based screening would become cost-effective if test costs fell below $131.7 or colonoscopy uptake increased to at least 70% for NMPAmin and 50% for blood-based tests and mt-sDNA. Limitations include the assumption of a one-time screening scenario; future iterations of the model and merging evidence in repeated screening will address these limitations. CONCLUSION: Improving screening participation could enhance health benefits and cost-efficiency in CRC screening. Questionnaire-based risk assessment combined with FIT was a cost-effective strategy in China, whereas non-invasive biomarker-based methods require cost reduction and higher uptake to justify adoption. These findings provide evidence for policymakers to optimize CRC screening programs.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Xie J, Dong X, Luo Z, et al. The impact of adherence on colorectal cancer screening cost-effectiveness: A modeling study. PLoS Med. 2025. PMID: 41296753. doi:10.1371/journal.pmed.1004807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。